|1.||Runge, Val M: 8 articles (01/2013 - 05/2009)|
|2.||Attenberger, Ulrike I: 6 articles (11/2012 - 05/2009)|
|3.||Reiser, Maximilian F: 5 articles (11/2014 - 07/2007)|
|4.||Morelli, John N: 5 articles (11/2012 - 03/2010)|
|5.||Kauczor, Hans-Ulrich: 5 articles (06/2010 - 02/2004)|
|6.||Tombach, Bernd: 5 articles (03/2009 - 01/2002)|
|7.||Kramer, Ulrich: 4 articles (11/2015 - 01/2008)|
|8.||Loewe, Christian: 4 articles (06/2015 - 09/2003)|
|9.||Taupitz, Matthias: 4 articles (04/2014 - 09/2003)|
|10.||Schoenberg, Stefan O: 4 articles (11/2012 - 05/2009)|
|1.||Neoplasm Metastasis (Metastasis)
01/01/2014 - "Both 1-minute and 5-minute-delayed imaging after gadobutrol injection appears to be effective for the detection of intracerebral metastases."
08/01/1995 - "In a clinical phase-II study 20 patients who had been diagnosed as having brain metastases with CT or MRT were studied prospectively with Gadobutrol, a new nonionic, low osmolality contrast agent. "
01/01/2014 - "Twenty-one patients with intracerebral metastases underwent contrast-enhanced MR with three-dimensional T1-weighted sequence at 1 minute, 5 minutes and 10 minutes after a single dose injection of gadobutrol. "
01/01/2014 - "To compare the effect of imaging time delay on the MR detection of intracerebral metastases using single dose gadobutrol. "
01/01/2014 - "Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol."
|2.||Body Weight (Weight, Body)
03/01/2007 - "The GFR was assessed by recording the renal clearance of gadobutrol (3.75 mL, approximately 0.05 mmol per kilogram of body weight) at navigator-gated turbo fast low-angle shot magnetic resonance (MR) imaging. "
03/01/2009 - "This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. "
09/01/2003 - "The study included 50 patients, with 25 patients (group 1) injected with 0.2 mmol Gd-GTPA/kg body weight and 25 patients (group 2) injected with 0.1 mmol gadobutrol/kg body weight. "
07/01/1994 - "In this article, the authors report on the first application of gadobutrol in humans, up to a dose of 0.5 mmol/kg. Gadobutrol was investigated after single intravenous administration in two phase-1 studies testing low (0.5 mol/L) and high concentrations (1 mol/L) in healthy, male volunteers using a double-blind, randomized, placebo-controlled study with n = 55 for the low concentration (0.04, 0.1, 0.2, 0.3, and 0.4 mmol/kg body weight), followed by n = 36 for the high concentration (0.3, 0.4, and 0.5 mmol/kg body weight). "
01/01/2016 - "Pediatric subjects (term newborns to those aged younger than 2 years) with normal renal function undergoing magnetic resonance imaging with gadobutrol (0.1 mmol/kg body weight [BW]) were prospectively enrolled in this open-label, multicenter clinical trial to evaluate PK as a primary end point. "
|3.||Hepatocellular Carcinoma (Hepatoma)
01/01/1999 - "The efficacy of a 1.0 molar formulation of gadobutrol was compared with that of a 0.5 molar formulation in dynamic magnetic resonance (MR) imaging of the liver in rats with hepatocellular carcinoma (HCC). "
01/01/1999 - "Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma."
01/01/2008 - "The purpose of this study was to compare the diagnostic efficacy of double-dose 1.0-M gadobutrol with that of standard-dose 0.5-M gadopentetate dimeglumine for revealing small hypervascular hepatocellular carcinomas (HCCs). "
01/01/2008 - "Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas."
07/01/2015 - "Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol."
|4.||Brain Neoplasms (Brain Tumor)
12/01/1997 - "[Safety and use of gadobutrol in patients with brain tumors (phase III trial)]."
05/01/2009 - "This result with gadobutrol may facilitate better brain tumor detection in the presence of blood-brain barrier disruption."
11/01/1995 - "In preliminary imaging experiments, gadobutrol caused high enhancement in different lesions (cerebral infarct, brain tumor) of the rat. "
05/01/2009 - "Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T."
05/01/2010 - "The purpose of this article is to evaluate the efficacy of a single dose of gadobutrol (0.1 mmol/kg of body weight) compared with that of a substantially higher dose of gadoterate meglumine (0.15 mmol/kg of body weight) in a rat brain tumor model at 1.5 and 3 T. "
03/01/2010 - "In group 3 the improvement in tumor SNR and CNR seen with the increase in field strength from 1.5 to 3 T for gadobutrol was statistically significant at all acquired timepoints (P < 0.002). "
03/01/2010 - "A substantial further improvement in tumor enhancement was noted using gadobutrol at 3 T."
01/01/2015 - "ACPPD-Gd tended to improve tumor detection by an experienced reader (AUC 0.98 vs 0.91) and significantly more for a trainee (0.93 vs. 0.82, p = 0.02) compared to gadobutrol. "
01/01/2015 - "T1-weighted (T1w) tumor signal normalized to muscle, was compared among the non-contrast, gadobutrol, and ACPPD-Gd groups using ANOVA. "
01/01/2015 - "We evaluated the impact of flip angle (FA) and repetition time (TR) on the ERmax values of dynamic gadobutrol-enhanced MR imaging, obtaining T1-weighted (T1W) MR imaging of VX2 tumors using 2-dimensional fast spoiled gradient echo (2D FSPGR) with various FAs (30°, 60° and 90°) at 1.5 tesla before and after injection of 0.1 mmol/kg gadobutrol. "
|1.||Gadolinium DTPA (Magnevist)
|5.||gadobenic acid (gadobenate dimeglumine)
|6.||gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetate
|10.||gadolinium ethoxybenzyl DTPA
|5.||Homologous Transplantation (Allograft)